Independent service organization InnoServ Technologies of Corona,CA, has named Michael Puls as president and CEO. Puls fills aleadership role formerly held by Alan Margulis, who left the companyin March (SCAN 3/29/95). Puls moves to InnoServ from Senmed
Independent service organization InnoServ Technologies of Corona,CA, has named Michael Puls as president and CEO. Puls fills aleadership role formerly held by Alan Margulis, who left the companyin March (SCAN 3/29/95). Puls moves to InnoServ from Senmed MedicalVentures, which specializes in medical venture capital financing.
InnoServ reported second-quarter financial results (end-October)earlier this month. Revenues were $11.9 million with net incomeof $185,000, compared to sales of $13.4 million and a net lossof $528,000 in the same period last year.
For the first six months of the year, InnoServ posted revenuesof $23.9 million with net income of $71,000, compared to revenuesof $22.1 million and a net loss of $1.1 million in the same periodin 1994. InnoServ also announced that it had received a five-year$5.5 million contract for biomedical and clinical lab repair servicesat Children's Hospital in Columbus, OH.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.